Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

However, the nation has now been embroiled in this "war" for over 50 years, and we are nowhere closer to victory, argues ...

HIGHLIGHTS Relapse after remission on TKI can harbor mutations in ABL1, RAS, or neither Mutations and development-like cell state dictate fitness in residual disease Co-targeting cell state and ABL1 ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Roche/Chugai’s pan-RAS inhibitor LUNA18 has already completed ... builds on AZ’s “heritage of targeting tumour drivers and mutations.” He added that the deal “could accelerate the ...

Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 103,800 shares, a ...

Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...

The Securities and Exchange Board of India (SEBI) has eased compliance requirements for Research Analysts (RAs) and Investment Advisors (IAs), allowing them to inform existing clients about the Most ...